PMID: 9179072Jun 1, 1997Paper

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B

Cancer
N J YogelzangMark R Green

Abstract

Malignant mesothelioma is a disease that is refractory to chemotherapy. Therefore, the objective of this multi-institutional, cooperative group Phase II trial was to determine the efficacy of dihydro-5-azacytidine (DHAC), a pyrimidine analogue, in the treatment of malignant mesothelioma. Forty-one patients with histologically confirmed malignant mesothelioma received 120-hour continuous infusions of DHAC (1,500 mg/m2/day every 21 days) until maximal response, intolerable toxicity, or disease progression. One patient had a complete response, two had objective partial responses, and four had regression of evaluable disease. The overall response rate was 17%. The one complete responder remains without disease progression at 6 years. Chest pain and nausea were the most common toxicities. Supraventricular tachycardia and pericardial effusion occurred in 20% and 15% of patients, respectively. In most patients, gastrointestinal effects were manageable. There was no significant hematologic toxicity. In malignant mesothelioma, a disease that is refractory to chemotherapy, dihydro-5-azacytidine has definite antitumor activity. Its modest hematologic toxicity profile favors its use in combination with other agents. Caution regarding cardi...Continue Reading

References

Jan 1, 1990·Cancer Chemotherapy and Pharmacology·N J VogelzangM R Green
Jan 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D RaghavanB McCaughan
Jan 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K AntmanJ Corson
Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S AlbertsC A Van der Merwe
Jun 1, 1982·Annals of Internal Medicine·A P ChahinianE M Mandel
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J VogelzangM R Green
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P ChahinianL Leone
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D J SugarbakerK H Antman
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S T Ong, N J Vogelzang

❮ Previous
Next ❯

Citations

Apr 27, 2007·Journal of Cellular Physiology·Luca SigalottiMichele Maio
May 14, 2011·Epigenetics : Official Journal of the DNA Methylation Society·Marika MatoušováHelena Mertlíková-Kaiserová
Aug 29, 2002·Cancer Investigation·Keith M Skubitz
Mar 1, 2003·British Journal of Cancer·S TomekC Manegold
Nov 28, 2008·Molecular Diagnosis & Therapy·Laurent GreillierAlexandre Passioukov
Jun 2, 2012·Future Medicinal Chemistry·Marcela Krečmerová, Miroslav Otmar
Apr 18, 2013·Pharmacological Reviews·Detlev Boison
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Everett E VokesMark R Green
Mar 2, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Makoto TakenouchiKazunori Kato
Nov 27, 2020·Therapeutic Advances in Medical Oncology·Haitang YangRen-Wang Peng
Apr 4, 2021·Journal of Clinical Medicine·Sara LettieriGiulia M Stella
Nov 7, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Goffin, E Eisenhauer
Jul 21, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sandra Tomek, Christian Manegold
Jun 14, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Priya Kumar, Robert A Kratzke
Nov 5, 2003·Clinical Lung Cancer·Pasi A Janne
Feb 25, 2011·Cellular Signalling·Juan RenShi-Wen Jiang
May 31, 2011·Trends in Pharmacological Sciences·Roberto E Favoni, Tullio Florio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.